Full index of posts »
StockTalks
-
$GTSO Evaluates Tungsten Recycling Technology with Ambitions to Turn Waste into Wealth http://owl.li/b7E0f
35 minutes ago
-
$ISCO Offers Stem Cells with Unmatched Advantages http://owl.li/b6PkE
about 17 hours ago
-
How $SSNT Sets Itself Apart http://owl.li/b6vD9
about 21 hours ago
Latest Comments
-
QualityStocks on BioMedical Technology Solutions (BMTL.OB) Receives Russian Patent for Demolizer® II Technologies We simply offered coverage of the news back in ...
-
QualityStocks on CardioGenics (CGNH.OB) Inks “Key Milestone” Commercialization Agreement with Merck-Chimie Sorry, we don't. You can see companies we're cu...
-
pennymonkey on BioMedical Technology Solutions Holdings, Inc. (BMTL.OB) Announces the Signing of a Letter of Intent with New International Distributor Financials out soon for BMTLE
-
pennymonkey on BioMedical Technology Solutions (BMTL.OB) Receives Russian Patent for Demolizer® II Technologies BMTLE or BMTL making a comeback?
-
engindoc on CardioGenics (CGNH.OB) Inks “Key Milestone” Commercialization Agreement with Merck-Chimie Do you still follow Cardiogenics? (CGNH)Any upd...
Most Commented
- TouchIT Technologies Inc. (TUCN.OB) Reports Successful Second Quarter 2010 (7 Comments)
- Universal Detection Technology (UNDT.OB) Unveils Rapid Mold Detector (6 Comments)
- Portage Resources, Inc. (POTG) is “One to Watch” (5 Comments)
- Raystream Inc. (RAYS) Announces Change to Name and Trading Symbol (5 Comments)
- China-Biotics, Inc. (CHBT) Breaks New Ground by Winning First US Customer (4 Comments)
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.












View QualityStocks' Instablogs on:
International Stem Cell Corp. (ISCO) Offers Stem Cells With Unmatched Advantages
International Stem Cell Corp., based in Oceanside, California, is a stem cell therapeutics company with a powerful new stem cell technology called "parthenogenesis," which is expected to significantly advance the field of regenerative medicine by addressing the important issue of immune-rejection.
Parthenogenetic stem cells are derived from parthenogenetically activated human oocytes, where electrical or chemical stimuli replaces fertilization. Although not derived from fertilized eggs, these activated oocytes can be developed to the blastocyst stage which can give rise to a parthenogenetic stem cell line.
Of the several different types of stem cells, parthenogenetic stem cells (hpSCs) offer a unique combination of benefits. For one, parthenogenetic stem cells do not face the controversy associated with embryonic stem cells, which are derived from fertilized eggs (oocytes) that have the potential of developing into a human being. Neither do Parthenogenetic stem cells face the potential risks and regulatory scrutiny associated with induced pluripotent stem cells, which are differentiated cells that are chemically or otherwise driven back to earlier developmental stages requiring significant changes in gene expression that may have unknown biological impacts. Finally, parthenogenetic stem cells are not as limited in their ability to differentiate or proliferate as adult stem cells, which are difficult to obtain and work with.
In addition, different activation techniques applied to human oocytes allow the creation of either HLA heterozygous human parthenogenetic stem cell lines (hpSC), which are exactly HLA-matched/ histocompatible with the oocyte donors, or HLA homozygous hpSC, which may be histocompatible with significant segments of the human population.
The human parthenogenic stem cells pioneered by ISCO have the best characteristics of each of the other classes of stem cells. The ethical advantage of derivation from unfertilized parthenogeneticaly activated oocytes, combined with immune-matching advantage, makes hpSC a very promising source of pluripotent stem cells for cell-based transplantation therapy.
ISCO is the first company to have produced pluripotent human stem cell lines through the intentional use of parthenogenesis. To date ISCO has successfully derived and characterized 10 hpSC lines, including both HLA homozygous and HLA heterozygous lines. One of these lines (hpSC-Hhom-4) carries the most common HLA haplotype found across racial groups within the US population.
The company continues to make hpSCs available to academic and corporate research worldwide for their exploration of a wide range of disease targets.
For additional information, visit the company's website at InternationalStemCell.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net
Radian Group Inc. (RDN) Video Chart For Wednesday, May 23, 2012
RDN is a great example of a multiple-bottom chart that continues to bounce off of support. This video takes a look at that support level, as well as dynamic and static resistance points that are before the chart following the recent 30 percent climb.
To view the video chart, visit the following link: www.qualitystocks.net/videocharts
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net
OmniComm Systems, Inc. (OMCM) CRO Preferred Program Adds Veeda Oncology
OmniComm Systems is a provider of customer-driven Internet solutions to pharmaceutical, biotechnology, research, and medical device organizations that conduct clinical trial research both in the United States and Europe. It is one of the fastest growing companies in electronic data capture (EDC) marketplace today.
The company today announced that Veeda Clinical Research, Inc., also known as Veeda Oncology, has joined OmniComm's CRO Preferred Program. As part of this program, Veeda Oncology has signed an agreement to run their first study through the program, a 27-month, phase I oncology trial. This complex study will utilize OmniComm's TrailMaster EDC suite to manage their data collection, submission, and medical coding needs.
Veeda Oncology is a specialized global oncology clinical research organization capable of handling the rigors of phase I through phase IV trials. It is dedicated to providing comprehensive clinical oncology research services internationally for the pharmaceutical and biotechnology industries. It has offices located in the United States, Europe, India, and Malaysia.
Omnicomm's CRO Preferred Program was chosen by Veeda because of the company's experience and expertise in conducting oncology trials. And Veeda is not the first company to do so. The addition of Veeda Oncology brings the membership total in the Program to 48 clinical research organizations. They are drawn by members exclusive benefits including sales and marketing support, training and having a having a dedicated, hosted environment all at a fixed, pay-as-you-go price.
For additional information about OmniComm Systems and the services it offers, please visit the company's website at OmniComm.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net